Symrise announced it has acquired a 20% stake in U.S. biotechnology firm Therapeutic Peptides Inc. (TPI). The deal that will give Symrise exclusive distribution rights for a group of peptide-based active cosmetic ingredients. Symrise stated that the deal will help strengthen its position in the active ingredients sector, especially with peptides popularity in the antiaging market. TPI reportedly will gain R&D opportunities and worldwide distribution. Financial terms were not disclosed.